Diagnostic value of different anti-citrullinated peptides antibodies in rheumatoid arthritis
- PDF / 84,771 Bytes
- 1 Pages / 595.28 x 793.7 pts Page_size
- 63 Downloads / 176 Views
POSTER PRESENTATION
Open Access
Diagnostic value of different anti-citrullinated peptides antibodies in rheumatoid arthritis Estíbaliz Ruiz-Ortiz de Arrizabaleta1,2, Dolors Grados-Cánovas3, Aina Teniente-Serra1,2, Virginia García-López1,2, Bibiana Quirant-Sánchez1,2, Susana Holgado3, Alejandro Olivé3, Ricardo Pujol-Borrell2,4, Eva Martínez-Cáceres1,2* From 6th European Workshop on Immune-Mediated Inflammatory Diseases Nice, France. 23-25 November 2011 Introduction Assays that detect anti-citrullinated peptides antibodies (ACPA) are considered to be more specific than rheumatoid factor in the diagnosis of rheumatoid arthritis (RA). Several tests have been developed using different antigens: first, second and third-generation cyclic-ACPA (CCP1, CCP2, CCP3) and modified citrullinated vimentin (MCV). Aim To investigate anti-CCP3 in a group of patients positive citrullinated vimentin antibodies (MCVA). Patients and methods A total of 259 patients positive for IgG MCVA+ attending the outpatient rheumatology clinic of a single general hospital (HUGTiP) were tested for anti-CCP3 (by ELISA). From the total, 182 (70.3%) of them had a rheumatic disease (RD): RA in 121 (66.5%) and other RDs in 61 (33.5%). 77 (29.7%) patients with other conditions positive for MCVA were also tested for anti-CCP3.
RDs). Positive and negative predictive values (PPV, NPV) of anti-CCP3 for RA were 85.5% and 88.8%, respectively whereas PPV for anti-MCV was 39.1%.
Conclusions Anti-CCP3 antibodies show a higher specificity for RA when compared to MCVA with a better PPV, a crucial feature for a test in use for clinical practice. Author details 1 Immunology Laboratory, Banc de Sang I Teixits, Hospital Universitari Germans Trias i Pujol (HUGTP), Badalona, Spain. 2Dept. of Cell Biology, Physiology and Immunology, Faculty of Medicine, Universitat Autònoma Barcelona, Spain. 3Rheumatology Division, HUGTP, Badalona, Spain. 4 Immunology Division, Hospital Universitari Vall d’Hebron, Barcelona, Spain. Published: 23 November 2011
doi:10.1186/1479-5876-9-S2-P51 Cite this article as: Ruiz-Ortiz de Arrizabaleta et al.: Diagnostic value of different anti-citrullinated peptides antibodies in rheumatoid arthritis. Journal of Translational Medicine 2011 9(Suppl 2):P51.
Results From the 121 RA patients, 106 (87.6%) were positive for anti-CCP3. In contrast, only 15 (24.6%) of the 61 patients without RA and only 4 (5.2%) of the 77 MCVA + patients with no RD associated were CCP3 positive. Interestingly, within the group no RA, of the 13 patients with anti-CCP3 values >60 U/ml, 6 (46.2%) were cases of palindromic rheumatism and two of them had developed RA. Specificity of anti-CCP3 for RA as compared to other RDs was 76.7%, that raised to 86.9% when comparing RA versus to non-RA (with or without another
• Convenient online submission
1 Immunology Laboratory, Banc de Sang I Teixits, Hospital Universitari Germans Trias i Pujol (HUGTP), Badalona, Spain Full list of author information is available at the end of the article
Submit your manuscript at www.biomedcentral.co
Data Loading...
